구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials·t½ ADC ~3.4 days; free MMAE ~2.4 days | |||
|---|---|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Herceptin (trastuzumab) | Tecentriq (atezolizumab) | Padcev (enfortumab vedotin) |
Overview Company | Merck | Roche / Genentech | Roche / Genentech | Astellas / Pfizer (Seagen) |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ADC |
Overview Target | PD-1 | HER2 | PD-L1 | Nectin-4 |
Overview Indication | Multiple solid tumors | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | Locally advanced or metastatic urothelial carcinoma |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) | novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. |
Positioning Known limitation | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. | resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes | resistance to existing therapies | Nectin-4 loss, MMAE efflux, and tubulin alterations. |
Positioning Development positioning | Global IO standard | — | — | 1L standard of care in urothelial carcinoma with pembrolizumab. |
Technology Payload | — | — | — | MMAE (monomethyl auristatin E, tubulin inhibitor) |
Technology Linker | — | — | — | Protease-cleavable mc-vc-PAB, DAR ~3.8 |
Technology DAR | — | — | — | DAR 3.8 |
MoA Mechanism | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. |
MoA Biomarker | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. |
PK/PD Half-life | 22 h | 4 h | 27 h | ADC ~3.4 days; free MMAE ~2.4 days |
PK/PD Species | Mouse, Radiographic response, ctDNA clearance in some tumors | Mouse, OS in metastatic BC | Mouse, Human | Cynomolgus monkey, ORR, PFS, OS |
PK/PD Animal (cat.) | Mouse, In vitro | Mouse, In vitro | Human, Mouse | Human, NHP, In vitro |
PK/PD Experiment | PD | Pharmacokinetic | PD | Pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse, Rat | Mouse, Rat | Cynomolgus monkey, Mouse, Human | Cynomolgus monkey, Mouse, Rat |
Toxicology Major finding | Immune-related AEs | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. |
Toxicology CRS | N/A | N/A | N/A | N/A |
Clinical Safety signal | Immune-related AEs | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. |
Clinical Selected reported efficacy | ORR 38% | ORR 91.2% | — | ORR 67.7% |
Clinical Reported ORR | 38% | 91.2% | — | 67.7% (EV + pembrolizumab) |
Clinical Reported PFS | — | — | 1.7 | 12.5 mo vs 6.3 mo (chemo) |
Clinical Reported OS | — | — | 7.6 | 31.5 mo vs 16.1 mo (chemo) |
Clinical Result source | ClinicalTrials.gov NCT02444741 | ClinicalTrials.gov NCT02149524 | ClinicalTrials.gov NCT04457778 | EV-302 / KEYNOTE-A39 (NCT04223856) |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02444741 | NCT02149524 | NCT04457778 | NCT04223856 |
Preclinical Animal (cat.) | — | — | Mouse | Human, Mouse, In vitro |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials·t½ ADC ~3.4 days; free MMAE ~2.4 days | |||
|---|---|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Herceptin (trastuzumab) | Tecentriq (atezolizumab) | Padcev (enfortumab vedotin) |
Overview Company | Merck | Roche / Genentech | Roche / Genentech | Astellas / Pfizer (Seagen) |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ADC |
Overview Target | PD-1 | HER2 | PD-L1 | Nectin-4 |
Overview Indication | Multiple solid tumors | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | Locally advanced or metastatic urothelial carcinoma |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) | novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. |
Positioning Known limitation | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. | resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes | resistance to existing therapies | Nectin-4 loss, MMAE efflux, and tubulin alterations. |
Positioning Development positioning | Global IO standard | — | — | 1L standard of care in urothelial carcinoma with pembrolizumab. |
Technology Payload | — | — | — | MMAE (monomethyl auristatin E, tubulin inhibitor) |
Technology Linker | — | — | — | Protease-cleavable mc-vc-PAB, DAR ~3.8 |
Technology DAR | — | — | — | DAR 3.8 |
MoA Mechanism | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. |
MoA Biomarker | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. |
PK/PD Half-life | 22 h | 4 h | 27 h | ADC ~3.4 days; free MMAE ~2.4 days |
PK/PD Species | Mouse, Radiographic response, ctDNA clearance in some tumors | Mouse, OS in metastatic BC | Mouse, Human | Cynomolgus monkey, ORR, PFS, OS |
PK/PD Animal (cat.) | Mouse, In vitro | Mouse, In vitro | Human, Mouse | Human, NHP, In vitro |
PK/PD Experiment | PD | Pharmacokinetic | PD | Pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse, Rat | Mouse, Rat | Cynomolgus monkey, Mouse, Human | Cynomolgus monkey, Mouse, Rat |
Toxicology Major finding | Immune-related AEs | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. |
Toxicology CRS | N/A | N/A | N/A | N/A |
Clinical Safety signal | Immune-related AEs | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. |
Clinical Selected reported efficacy | ORR 38% | ORR 91.2% | — | ORR 67.7% |
Clinical Reported ORR | 38% | 91.2% | — | 67.7% (EV + pembrolizumab) |
Clinical Reported PFS | — | — | 1.7 | 12.5 mo vs 6.3 mo (chemo) |
Clinical Reported OS | — | — | 7.6 | 31.5 mo vs 16.1 mo (chemo) |
Clinical Result source | ClinicalTrials.gov NCT02444741 | ClinicalTrials.gov NCT02149524 | ClinicalTrials.gov NCT04457778 | EV-302 / KEYNOTE-A39 (NCT04223856) |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02444741 | NCT02149524 | NCT04457778 | NCT04223856 |
Preclinical Animal (cat.) | — | — | Mouse | Human, Mouse, In vitro |
추천 비교
추천 비교